cells/well in DMEM supplemented with 10% FBS and cultured for 24 hours. The medium was then replaced with serum-free Opti-MEM medium (Gibco-BRL) and the cells were incubated with 1.0 µg/ml recombinant human DcR3-Fc protein (DcR3-Fc: R&D Systems) or 1.0 µg/ml control IgG1 (R&D Systems) for 12 hours, or 1.0 ng/ml recombinant human TNFα (R&D Systems, Minneapolis, MN) or 1.0 ng/ml IL-1β (R&D Systems) for 24 hours. After the incubation, RNA was extracted with QIAshredder and RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacture's protocol and reverse-transcribed to first-strand cDNA. The relative expression levels of mRNAs were compared using TaqMan® real-time PCR on a StepOne™ real-time PCR system (Applied Biosystems, Foster City, CA). Pre-designed primers and probes for TPH1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control were obtained from Applied Biosystems. Immunohistochemistry. Mouse anti-human serotonin monoclonal antibody (AnaSpec, San Jose, CA) diluted 1:20 was applied to 9 μm frozen sections of rheumatoid synovial tissues cut on a cryostat for overnight. HistoFine Simple Stain Kit (Nichirei, Tokyo, Japan) with peroxidase was used as a secondary antibody, and the sections were developed with DAB, followed by counterstaining with hematoxylin. Stained sections were photographed with Axioskop 2 plus (Carl Zeiss Microscopy, LLC, USA). Results: TPH1 mRNA was expressed in both RA and OA-FLS (Fig. 1) . TPH1 mRNA expression was decreased significantly, 0.71-fold, by DcR3-Fc in RA-FLS, but was not influenced in OA-FLS (Fig. 2) . Meanwhile, TPH1 mRNA expression was significantly decreased by TNFα or IL-1β both in RA and OA-FLS (Fig. 3) . TPH1 mRNA expression in RA-FLS was suppressed to 0.45-fold by TNFα and 0.27-fold by IL-1β, and that in OA-FLS was suppressed to 0.52-fold by TNFα and 0.34-fold by IL-1β respectively. Immunohistochemistry confirmed that serotonin was present in RA-FLS (Fig. 4) . Discussion: In this study, we first revealed that the expression of TPH1 in FLS was down-regulated by inflammatory cytokines and that TPH1 in RA-FLS was suppressed by DcR3 in a disease-specific fashion. Previous studies suggested that serotonin has pleiotropic effects other than physiological functions. For example, serotonin synthetized by TPH1 in the periphery has functions in immune system and vasoconstriction [9] . Especially, serotonergic pathways play an important role in modulating inflammatory pain, compared with mechanistic pain [10] . Further, serotonin decreases osteoblast proliferation and bone formation [10] and increases the total number of differentiated human osteoclasts as well as osteoclast activity [11] . Although the inflammatory cytokines suppress TPH1 expression both in RA-FLS and OA-FLS, DcR3 suppresses only in RA-FLS. Therefore, TPH1 expression in RA-FLS regulated by DcR3 in a disease specific manner may affect serotonin expression to be involved in the pathogenesis of RA, such as modulating inflammatory pain and bone remodeling. Both DcR3 and TPH1 could be a possible therapeutic target of RA. Significance: The correlation between DcR3 and TPH1 in RA-FLS was newly revealed. 
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